Exemple de utilizare a A third study în Engleză și traducerile lor în Română
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Computer
-
Programming
This is the second@SamKnows study(with a third study planned in 2014).
A third study compared TachoSil with standard stitching in 185 patients having kidney surgery.
The main measure of effectiveness was the reduction in the levels of HIV in the blood(viral load)after 16 weeks; a third study involved 566 patients who had not taken HIV treatment before and compared Isentress with efavirenz(another anti-HIV medicine).
A third study investigated the effectiveness of Kalydeco in patients with cystic fibrosis due to several mutations other than G551D.
The efficacy and toxicity of a variation of the Zevalin therapeutic regimen employing a reduced activity of[90Y]-Zevalin was further defined in a third study enrolling a total of 30 patients who had mild thrombocytopenia(platelet count 100,000 to 149,000 cells/ mm3).
Oamenii se traduc, de asemenea,
In a third study, 254 pigs infected with Trichuris suis were treated either with Panacur AquaSol or received no treatment.
The efficacy and safety of a variation of the Zevalin therapeutic regimen employing a reduced dose of ibritumomab tiuxetan[90Y] was further defined in a third study enrolling a total of 30 patients who had mild thrombocytopenia(platelet count 100,000 to 149,000 cells/mm3).
A third study in 776 children compared the effects of M-M-RVAXPRO when given as injected into the muscle and when injected under the skin.
In children, the ability of Prevenar 13 to trigger the production of antibodies(immunogenicity)was assessed in two main studies involving 1,266 healthy children who were vaccinated between the ages of two and 15 months and in a third study involving 598 children aged between five and 17 years old who had previously been vaccinated with Prevenar or who had never been vaccinated for invasive pneumococcal disease.
A third study involving 139 patients compared Instanyl with fentanyl as a‘transmucosal' tablet(absorbed through the lining of the mouth).
A third study compared Forxiga with a sulphonylurea(glipizide), both taken in combination with metformin in 814 patients.
In a third study, a pre-specified analysis demonstrated efficacy over placebo for 100 mg/day and 200 mg/day in patients with prior exposure to levetiracetam.
A third study examined the use of Privigen for immunomodulation in 28 patients with CIDP who were given Privigen every three weeks over a period of 24 weeks.
A third study looked at around 1,000 patients with lung cancer who had had at least one previous chemotherapy treatment and whose tumours produced PD-L1.
A third study, which involved 900 adults aged 18 to 49, compared the immune response to Prevenar 13 with the response in adults aged 60 to 64.
A third study involved 57 patients with partial-thickness burn wounds who had half their wound treated with Episalvan and the other half with a standard disinfectant gel.
In a third study in adults aged 50-93 years, it was demonstrated that Prevenar 13 may be given concomitantly with the seasonal quadrivalent inactivated influenza vaccine(QIV).
A third study, using a vaccine with strain A/turkey/Turkey/1/05(H5N1)-like strain(NIBRG-23), has been carried out in 343 adults aged below and above 60 years.
A third study in 419 patients looked mainly at how effective Tagrisso was at preventing the cancer from worsening, comparing it with a platinum-based chemotherapy(the standard treatment for NSCLC).
In addition, a third study is ongoing in 5,623 patients where previous treatment with another disease-modifying therapy had failed(glatiramer acetate, beta-interferon or fingolimod).
A third study looked at 332 patients with complicated intra-abdominal or urinary tract infections caused by Gram-negative bacteria that were resistant to ceftazidime(could not be killed by ceftazidime).
A third study, D9902A, similar in design to study D9901, was terminated prior to completion of planned accrual based on the time to disease progression results in study D9901.
In a third study, Rixubis was given to 14 patients undergoing surgery; treatment with Rixubis kept blood loss during the surgery to levels expected in patients without haemophilia B.
A third study, in 578 patients whose disease had not responded or had come back after previous treatment, compared adding Imbruvica or placebo(a dummy treatment) to the cancer medicines bendamustine and rituximab.
In a third study in patients with cancer of the head and neck including mouth cancer, Lymphoseek was used to detect sentinel lymph nodes before patients had their lymph nodes removed surgically.
A third study in previously untreated patients compared the effects of giving peginterferon alfa and ribavirin for different lengths of time(either six months or one year) together with three months of Incivo treatment.
In a third study in patients who had been treated before, Telzir was less effective than the comparator medicine lopinavir, with patients taking lopinavir having larger reductions in viral loads over the first 48 weeks.
A third study studied the effects of Ultibro Breezhaler on the rate of exacerbations(flare-ups) patients experienced during 64 weeks of treatment when compared with treatment with glycopyrronium or tiotropium(other treatments for COPD).
A third study(study 3) primarily evaluated the safety of Xolair in patients with CSU who remained symptomatic despite treatment with H1 antihistamines at up to four times the approved dose and H2 antihistamine and/or LTRA treatment.
A third study compared Tarceva with placebo in 643 patients with advanced NSCLC whose cancer cells did not have EGFR activating mutations and whose disease was stable after initial treatment with four cycles of platinum-containing chemotherapy.